$Pseudomonas\ aeruginosa$ antimicrobial susceptibility profiles, resistance mechanisms and international clonal lineages: update from ESGARS-ESCMID/ISARPAE Group - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Clinical Microbiology and Infection Année : 2023

$Pseudomonas\ aeruginosa$ antimicrobial susceptibility profiles, resistance mechanisms and international clonal lineages: update from ESGARS-ESCMID/ISARPAE Group

1 IdISBa - Fundació Institut d'Investigació Sanitària Illes Balears
2 INIBIC - Instituto de Investigación Biomédica de A Coruña [La Corogne, Espagne]
3 Department of Medical Microbiology, Amerikan Hastanesi, Istanbul, Turkey
4 CHU UCL Namur
5 Hospital Universitario Ramón y Cajal [Madrid]
6 University of Oldenburg
7 Erasmus MC - Erasmus University Medical Center [Rotterdam]
8 Karolinska Institutet [Stockholm]
9 Karolinska University Hospital [Stockholm]
10 ICSN - Institut de Chimie des Substances Naturelles
11 Växjö Central Hospital
12 Semmelweis University [Budapest]
13 UNIBE - Universität Bern / University of Bern
14 Universiteit Antwerpen = University of Antwerpen [Antwerpen]
15 IMIBIC - Instituto Maimonides de Investigación Biomédica de Cordoba
16 UNIVR - Università degli studi di Verona = University of Verona
17 RESINFIT - Anti-infectieux : supports moléculaires des résistances et innovations thérapeutiques
18 Team Resist [Le Kremlin-Bicêtre]
19 RIVM - National Institute for Public Health and the Environment [Bilthoven]
20 ISC - Instituto de Salud Carlos III [Madrid]
21 UNN - University Hospital of North Norway [Tromsø]
22 University of Ljubljana
23 UTAD - University of Trás-os-Montes and Alto Douro [Portugal]
24 UNIFR - Université de Fribourg = University of Fribourg
25 NKUA - National and Kapodistrian University of Athens
26 UiT - The Arctic University of Norway [Tromsø, Norway]
27 University of Zagreb
28 Tsaritsa Yoanna University Hospital = Queen Giovanna University Hospital [Sofia]
29 LUSH - Lithuanian University of Health Science
30 LCE - Laboratoire Chrono-environnement (UMR 6249)
Pierre Bogaerts
  • Fonction : Auteur
Olivier Denis
  • Fonction : Auteur
Bogdan I. Iorga

Résumé

Scope Pseudomonas aeruginosa, a ubiquitous opportunistic pathogen considered one of the paradigms of antimicrobial resistance, is among the main causes of hospital-acquired and chronic infections associated with significant morbidity and mortality. This growing threat results from the extraordinary capacity of P. aeruginosa to develop antimicrobial resistance through chromosomal mutations, the increasing prevalence of transferable resistance determinants (such as the carbapenemases and the extended spectrum β-lactamases), and the global expansion of epidemic lineages. The general objective of this initiative is to provide a comprehensive update of P. aeruginosa resistance mechanisms, especially for the extensively drug-resistant (XDR)/difficult to treat resistance (DTR) international high-risk epidemic lineages, and how the recently approved β-lactams and β-lactam/β-lactamase inhibitor combinations may affect resistance mechanisms and the definition of susceptibility profiles. Methods To address this challenge, the European Study Group for Antimicrobial Resistance Surveillance (ESGARS) from the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) launched the “Improving Surveillance of Antibiotic-Resistant Pseudomonas aeruginosa in Europe” (ISARPAE) initiative in 2022, supported by the Joint programming initiative on antimicrobial resistance (JPIAMR) network call and included a panel of over 40 researchers from 18 European Countries. Thus, an ESGARS-ISARPAE position paper was designed and the final version agreed after four rounds of revision and discussion by all panel members. Questions addressed in the position paper To provide an update on (i) the emerging resistance mechanisms to classical and novel antipseudomonal agents, with a particular focus on β-lactams, (ii) the susceptibility profiles associated with the most relevant β-lactam resistance mechanisms, (iii) the impact of the novel agents and resistance mechanisms on the definitions of resistance profiles and (iv) the globally expanding XDR/DTR high-risk lineages and their association with transferable resistance mechanisms. Implication The evidence presented herein can be used for coordinated epidemiological surveillance and decision-making at the European and global level.

Domaines

Bactériologie
Fichier principal
Vignette du fichier
manuscript_CMI_Paeruginosa.pdf (541.27 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-04384072 , version 1 (10-01-2024)

Identifiants

Citer

Antonio Oliver, Estrella Rojo-Molinero, Jorge Arca-Suarez, Yeşim Beşli, Pierre Bogaerts, et al.. $Pseudomonas\ aeruginosa$ antimicrobial susceptibility profiles, resistance mechanisms and international clonal lineages: update from ESGARS-ESCMID/ISARPAE Group. Clinical Microbiology and Infection, In press, ⟨10.1016/j.cmi.2023.12.026⟩. ⟨hal-04384072⟩
43 Consultations
6 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More